Navigation Links
Cancer researchers add spice to research against rare neuromuscular disease

Scientists who focus on the molecular signaling that underlies prostate cancer have discovered a compound that shows promise against a debilitating neurodegenerative condition known as Kennedy's disease, which is caused by a mutant gene. Currently there is no treatment for the inherited disorder, which resembles a slowly progressive form of Lou Gehrig's disease and affects only men.

The compound, a distant chemical relative of a component of the spice curry, dramatically slowed the progression of the disease in mice that carried the mutant human gene that causes the disease. The mice were able to walk much more normally, their muscles were much stronger, and they had near-normal levels of a vital molecule crucial for keeping nerve cells healthy.

While a great deal more research needs to be done to see if the compound could be developed into a drug to help people with the disease, scientists say it's a promising development in a field where progress has been slow.

The research by scientists at the University of Rochester Medical Center appears in the March 6 issue of the journal Nature Medicine.

In their search for new treatments for prostate cancer and other diseases, Chawnshang Chang, Ph.D., and his colleagues have taken a few cues from centuries of Asian tradition, where curcumin ?the bright yellow spice found in curry powder ?has been used to treat a variety of ills. In the last decade, Western medicine has been putting curry to the test, finding that the spice offers promise against breast cancer, melanoma, Alzheimer's disease and the blisters that come with radiation treatments for cancer.

Chang notes that ginger, a family of spices that includes curcumin, is widely used in China as a folk medicine to treat male-pattern baldness. That condition is caused largely by the activity of the androgen receptor, the protein that is central to the action of testosterone and other male hormones. Chang's laboratory, in collabo
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Jump-starting T Cells In Skin Cancer
3. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
8. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
9. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
10. New Breast Cancer Test Could Save Lives
11. Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells

Post Your Comments:
(Date:11/25/2009)...e course of a lifetime, the heart pumps some 250 m...der to do this, the muscle fibers of the heart hav...ed by Dr. Wolfgang Rottbauer, vice chair of the De...Hospital (Chairman: Prof. Dr. H. A. Katus), has di...bility of the smallest muscular unit, the sarcomer...
(Date:11/24/2009)...us Research Institute (LRI) today named 12 new gra...million, recognize innovative work across a broad ...their creativity, novelty, and potential to drive ... and cure the complex disease of systemic lupus. ,...lupus researchers across the nation and include in...
(Date:11/24/2009)...mic-level action of a remarkable class of ring-sha...rs with the Lawrence Berkeley National Laboratory ...ystallography beamline at the Advanced Light Sourc...n gene expression and replication, and are vital t... infectious agents, such as the human papillomavir...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4NIMBioS hosts tutorial on optimal control and optimization for biologists 10071 1New Parkinsons Drug Draws Mixed Reviews 58192 1New Parkinsons Drug Draws Mixed Reviews 58192 2New Parkinsons Drug Draws Mixed Reviews 58192 3Minorities Less Likely to Have Blood Pressure Under Control 58190 1Minorities Less Likely to Have Blood Pressure Under Control 58190 2Minorities Less Likely to Have Blood Pressure Under Control 58190 3
..., , Svilen Bobev, assistant professor of chemistry...ce Foundation,s prestigious Faculty Early Career D...g award, designed to support the integrated resear...their careers, is bestowed on those scientists and...ic leaders of the 21st century. Fewer than 20 perc...
..., Researchers from the University of North Caroli...mechanism that may account for the development of ...e born with in the US every year. The findings, p...oS Computational Biology, add new knowledge to und... also point the way to new corrective treatments. ...
..., NEW YORK (Feb. 28, 2007) -- The general public ...ase (CKD) is a serious and progressive medical con...ed. Understandably so, since in its early stages C...the disease and their health-care providers unawar...r, if CKD is detected and treated early, its wides...
Other Biology News:UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 2UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 3Computer simulations point to key molecular basis of cystic fibrosis 2Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 2Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 3Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 4
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novembe...c. (Nasdaq: DCGN ) today announced the approval of...ptcy Court for the District of Delaware,(the "Bank... petition for,relief under Chapter 11 of the Unite.... , The orders issued by the Bankruptcy C...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/...ood & Drug Administration (SFDA) has approved ... its oral insulin project,(Nodlin), an innovative ...proval allows Biolaxy to initiate its first phase ...r characteristic of high blood glucose and poor,me...
(Date:11/24/2009)... , , Primary efficacy endpoint has been met... endometrial cancer, , QUEBEC CITY, Nov. 24 /...DAQ: AEZS ; TSX: AEZ) (the "Company"), a global b...apy and oncology, today announced positive efficac...toxic peptide conjugate, AEZS-108 (formerly AN-152...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-Fir...RNA ) announced today that the company is schedu...alth Care Conference on December 1, 2009 at 11:30 ...New York Palace Hotel in New York City. Jack Lief,... scheduled to provide an overview of the company, ...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
... Integrated Global Services, CAMBRIDGE, Mass., Ap...launches under a new name, Abt Bio-Pharma Solution...es Inc. The company will continue to,provide custo...for the,pharmaceutical, biotechnology, medical dev...proach that blends decades of experience with wide...
...08 Cardium Therapeutics,(Amex: CXM ) and its ope...at,InnerCool has entered into a European commercia...Euromed), a leading distributor of cardiology,medi...romed will have,exclusive marketing, sales and dis...nd for InnerCool,s portfolio of temperature modula...
... 1, 2008 Derma Sciences,Inc (OTC Bulletin Board: ...reported that sales for 2007 were $34.1 million, a...ported for 2006. Gross margins held steady at 34,p... in new products for the,pipeline, and expanding t...ny reported a loss of $2.3 million or $0.09 loss p...
Other Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
T4 Polynucleotide Kinase Exchange Reaction Buffer from Invitrogen
IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham Biosciences
IMAGEQUANT 100 WKSTN from GE Healthcare, formerly Amersham Biosciences
FlowTACS Flow Cytometry Apoptosis Detection Kit from R&D Systems
Biology Products: